We are live on ! Find out more
CRSP icon

CRISPR Therapeutics
CRSP

39 hedge funds and large institutions have $155M invested in CRISPR Therapeutics in 2017 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

11% more funds holding

Funds holding: 35 → 39 (+4)

0.2% less ownership

Funds ownership: 24.29% → 24.09% (-0.2%)

25% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 8

26% less capital invested

Capital invested by funds: $211M → $155M (-$55.7M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

100% less call options, than puts

Call options by funds: $1K | Put options by funds: $322K

Holders
39
Holders Change
+4
Holders Change %
+11.43%
% of All Funds
0.97%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
9
Increased
6
Reduced
8
Closed
5
Calls
$1K
Puts
$322K
Net Calls
-$321K
Net Calls Change
-$321K

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$12M
2
GIM
Granahan Investment Management
Massachusetts
+$2.87M
3
USAA
United Services Automobile Association
Texas
+$996K
4
Millennium Management
Millennium Management
New York
+$545K
5
RJA
Raymond James & Associates
Florida
+$331K

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$16.3M
2
A
Abingworth
United Kingdom
-$2.59M
3
NLVP
New Leaf Venture Partners
New York
-$970K
4
CCP
Clough Capital Partners
Massachusetts
-$456K
5
PC
Paulson & Co
New York
-$363K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$51.6M – – –
A
2
Abingworth
United Kingdom
$39M -$2.59M -157,005 -6%
CCP
3
Clough Capital Partners
Massachusetts
$12.8M -$456K -27,633 -3%
Morgan Stanley
4
Morgan Stanley
New York
$12M +$12M +727,196 +3,543%
Franklin Resources
5
Franklin Resources
California
$11.7M – – –
NLVP
6
New Leaf Venture Partners
New York
$8.45M -$970K -58,745 -10%
O
7
OrbiMed
New York
$5.96M – – –
NHAS
8
Novo Holdings A/S
Denmark
$3.58M – – –
GIM
9
Granahan Investment Management
Massachusetts
$2.79M +$2.87M +173,907 New
VC
10
Vivo Capital
California
$2.38M – – –
CS
11
Credit Suisse
Switzerland
$1.28M – – –
USAA
12
United Services Automobile Association
Texas
$966K +$996K +60,300 New
Millennium Management
13
Millennium Management
New York
$529K +$545K +33,000 New
PC
14
Paulson & Co
New York
$457K -$363K -22,000 -44%
RJA
15
Raymond James & Associates
Florida
$321K +$331K +20,009 New
Geode Capital Management
16
Geode Capital Management
Massachusetts
$294K -$45K -2,724 -13%
Vanguard Group
17
Vanguard Group
Pennsylvania
$273K +$281K +17,019 New
AIM
18
ARK Investment Management
Florida
$206K +$213K +12,888 New
Bank of America
19
Bank of America
North Carolina
$199K -$33.9K -2,050 -14%
Wells Fargo
20
Wells Fargo
California
$128K +$108K +6,560 +460%
PCMM
21
Private Capital Management (Minnesota)
Minnesota
$80K +$82.6K +5,000 New
Royal Bank of Canada
22
Royal Bank of Canada
Ontario, Canada
$53K -$842 -51 -2%
Bank of Montreal
23
Bank of Montreal
Ontario, Canada
$26K – – –
UBS Group
24
UBS Group
Switzerland
$25K +$15.8K +958 +168%
DBT
25
Dubuque Bank & Trust
Iowa
$23K – – –
1
2

CRSP Hedge Fund Activity: Q2 2017 in Review

39 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q2 2017, worth a combined $155M — down 26% from $211M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new CRSP positions and 5 closed out — a net gain of 4 holders — while 6 added to existing stakes and 8 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $12M. The largest seller was Wellington Management Group, exiting entirely with an estimated $16.3M sold.

  • 39 institutional investors held CRISPR Therapeutics (CRSP) as of Q2 2017, up from 35 in Q1 2017.
  • Funds reported $155M of CRISPR Therapeutics stock for Q2 2017, down 26% quarter-over-quarter.
  • 9 funds opened new CRISPR Therapeutics positions in Q2 2017 and 5 closed out, a net change of +4 holders.
  • The largest CRISPR Therapeutics buyer in Q2 2017 was Morgan Stanley, an estimated $12M added.
  • The largest CRISPR Therapeutics seller in Q2 2017 was Wellington Management Group, an estimated $16.3M sold.

Based on aggregated 13F filings for Q2 2017.